Infex Therapeutics, in collaboration with Justus-Liebig-University Giessen (JLU), Germany, has been awarded a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy). The company plans to develop a first-in-class BamA inhibitor targeting multi-drug-resistant (MDR) Gram-negative pathogens. BamA inhibitors are an entirely new class of antimicrobial drug designed to target infections caused by drug-resistant Gram-negative […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!